Jeonjinbio Co., Ltd. (KOSDAQ:110020)
South Korea · Delayed Price · Currency is KRW 1,760.00
+27.00 (1.56%)
At close: Jun 30, 2026
Jeonjinbio Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 14,421 | 13,694 | 19,273 | 15,681 | 7,794 | 3,214 |
Other Revenue | - | -0 | -0 | - | -0 | - |
| 14,421 | 13,694 | 19,273 | 15,681 | 7,794 | 3,214 | |
Revenue Growth (YoY) | -15.28% | -28.95% | 22.91% | 101.18% | 142.48% | -16.87% |
Cost of Revenue | 10,451 | 9,952 | 13,271 | 10,861 | 5,836 | 1,898 |
Gross Profit | 3,970 | 3,742 | 6,002 | 4,820 | 1,958 | 1,316 |
Selling, General & Admin | 3,385 | 3,426 | 3,359 | 3,937 | 3,346 | 3,716 |
Research & Development | 422.46 | 438.06 | 361.75 | 447.75 | 421.95 | 363.84 |
Amortization of Goodwill & Intangibles | 7.42 | 8.16 | 16.08 | 20.04 | 27.15 | 30.46 |
Other Operating Expenses | 91.37 | 87.52 | 142.94 | 134.69 | 111.8 | 82.76 |
Operating Expenses | 4,036 | 4,085 | 4,843 | 6,065 | 5,094 | 4,346 |
Operating Income | -65.59 | -342.85 | 1,158 | -1,245 | -3,136 | -3,030 |
Interest Expense | - | -0.33 | -432.26 | -1,195 | -2,035 | -865.67 |
Interest & Investment Income | 99.72 | 96.47 | 98.86 | 115.08 | 158.71 | 44.12 |
Currency Exchange Gain (Loss) | -19.7 | -5.81 | 6.35 | 2.71 | -25.17 | -8.62 |
Other Non Operating Income (Expenses) | 4.27 | 58.78 | 4,226 | -3,564 | 1,832 | 1,755 |
EBT Excluding Unusual Items | 18.71 | -193.74 | 5,057 | -5,886 | -3,205 | -2,105 |
Gain (Loss) on Sale of Assets | 1.09 | 1.09 | -456.58 | 9.94 | - | -2.91 |
Asset Writedown | -3.16 | -3.16 | -254.15 | -636.91 | - | - |
Other Unusual Items | - | - | - | 73.29 | 91.69 | - |
Pretax Income | 16.64 | -195.81 | 4,346 | -6,440 | -3,113 | -2,108 |
Net Income | 16.64 | -195.81 | 4,346 | -6,440 | -3,113 | -2,108 |
Net Income to Common | 16.64 | -195.81 | 4,346 | -6,440 | -3,113 | -2,108 |
Shares Outstanding (Basic) | 9 | 9 | 9 | 7 | 7 | 6 |
Shares Outstanding (Diluted) | 9 | 9 | 9 | 7 | 7 | 6 |
Shares Change (YoY) | 1.27% | 5.26% | 18.14% | 10.69% | 6.14% | 27.16% |
EPS (Basic) | 1.84 | -21.62 | 505.00 | -884.00 | -473.00 | -340.00 |
EPS (Diluted) | 1.84 | -21.62 | 505.00 | -884.00 | -473.00 | -340.00 |
Free Cash Flow | 1,031 | -305.9 | 2,616 | -960.95 | -5,705 | -4,232 |
Free Cash Flow Per Share | 114.05 | -33.77 | 303.93 | -131.91 | -866.77 | -682.57 |
Gross Margin | 27.53% | 27.32% | 31.14% | 30.74% | 25.13% | 40.94% |
Operating Margin | -0.46% | -2.50% | 6.01% | -7.94% | -40.23% | -94.26% |
Profit Margin | 0.11% | -1.43% | 22.55% | -41.07% | -39.94% | -65.59% |
Free Cash Flow Margin | 7.15% | -2.23% | 13.57% | -6.13% | -73.19% | -131.67% |
EBITDA | 487.49 | 192.7 | 2,500 | 590.48 | -1,744 | -2,663 |
EBITDA Margin | 3.38% | 1.41% | 12.97% | 3.77% | -22.37% | -82.84% |
D&A For EBITDA | 553.08 | 535.55 | 1,342 | 1,835 | 1,392 | 367.09 |
EBIT | -65.59 | -342.85 | 1,158 | -1,245 | -3,136 | -3,030 |
EBIT Margin | -0.46% | -2.50% | 6.01% | -7.94% | -40.23% | -94.26% |
Advertising Expenses | - | 86.01 | 94.99 | 219.26 | 164.76 | 374.4 |